Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Gains from Sales and Divestitures (2016 - 2025)

Ptc Therapeutics has reported Gains from Sales and Divestitures over the past 9 years, most recently at $90625.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $90625.0 for Q4 2025, down 90.59% from a year ago — trailing twelve months through Dec 2025 was $90625.0 (down 90.59% YoY), and the annual figure for FY2025 was $90625.0, down 90.59%.
  • Gains from Sales and Divestitures for Q4 2025 was $90625.0 at Ptc Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for PTCT hit a ceiling of $1.2 million in Q3 2025 and a floor of $90625.0 in Q4 2025.
  • Median Gains from Sales and Divestitures over the past 5 years was $726257.0 (2023), compared with a mean of $673204.4.
  • Biggest five-year swings in Gains from Sales and Divestitures: soared 82.33% in 2023 and later crashed 90.59% in 2025.
  • Ptc Therapeutics' Gains from Sales and Divestitures stood at $335114.0 in 2021, then surged by 50.65% to $504851.0 in 2022, then soared by 82.33% to $920488.0 in 2023, then increased by 4.68% to $963543.0 in 2024, then crashed by 90.59% to $90625.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $90625.0 (Q4 2025), $1.2 million (Q3 2025), and $1.1 million (Q2 2025) per Business Quant data.